Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 155 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling June 9, 2021 Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ January 6, 2020 The National Parks Service Still Hasn’t Fixed It’s Sexual Harassment Problem January 6, 2022 How and When to Wash Your Reusable Cloth Mask and When... November 30, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence...
